JP2024500932A - Ｒｎａウイルスおよび／または細菌誘発性の疾患の治療に対するｃｒｉｓｐｒ／ｃａｓ１３の応用 - Google Patents

Ｒｎａウイルスおよび／または細菌誘発性の疾患の治療に対するｃｒｉｓｐｒ／ｃａｓ１３の応用 Download PDF

Info

Publication number
JP2024500932A
JP2024500932A JP2023538702A JP2023538702A JP2024500932A JP 2024500932 A JP2024500932 A JP 2024500932A JP 2023538702 A JP2023538702 A JP 2023538702A JP 2023538702 A JP2023538702 A JP 2023538702A JP 2024500932 A JP2024500932 A JP 2024500932A
Authority
JP
Japan
Prior art keywords
grna
composition
cas13
protein
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538702A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022136370A5 (https=
JP2024500932A5 (https=
Inventor
クリストフ グルーバー
ドン－ジウン ジェフリー チュオン
フロリアン ギーサート
ヴォルフガング ヴルスト
Original Assignee
ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー filed Critical ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー
Publication of JP2024500932A publication Critical patent/JP2024500932A/ja
Publication of JPWO2022136370A5 publication Critical patent/JPWO2022136370A5/ja
Publication of JP2024500932A5 publication Critical patent/JP2024500932A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023538702A 2020-12-22 2021-12-21 Ｒｎａウイルスおよび／または細菌誘発性の疾患の治療に対するｃｒｉｓｐｒ／ｃａｓ１３の応用 Pending JP2024500932A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU102326 2020-12-22
LU102326 2020-12-22
PCT/EP2021/086992 WO2022136370A1 (en) 2020-12-22 2021-12-21 Application of crispr/cas13 for therapy of rna virus and/or bacterium induced diseases

Publications (3)

Publication Number Publication Date
JP2024500932A true JP2024500932A (ja) 2024-01-10
JPWO2022136370A5 JPWO2022136370A5 (https=) 2025-01-31
JP2024500932A5 JP2024500932A5 (https=) 2025-01-31

Family

ID=74626052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538702A Pending JP2024500932A (ja) 2020-12-22 2021-12-21 Ｒｎａウイルスおよび／または細菌誘発性の疾患の治療に対するｃｒｉｓｐｒ／ｃａｓ１３の応用

Country Status (6)

Country Link
US (1) US20240041990A1 (https=)
EP (1) EP4267736A1 (https=)
JP (1) JP2024500932A (https=)
CN (1) CN116917478A (https=)
CA (1) CA3203046A1 (https=)
WO (1) WO2022136370A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190002889A1 (en) * 2017-06-30 2019-01-03 Arbor Biotechnologies, Inc. Novel crispr rna targeting enzymes and systems and uses thereof
WO2019010422A1 (en) * 2017-07-07 2019-01-10 The Broad Institute, Inc. ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM
CN110656123A (zh) * 2019-10-12 2020-01-07 中国农业大学 基于CRISPR-Cas13d系统的sgRNA高效作用靶点的筛选方法及应用
JP2020511141A (ja) * 2017-03-15 2020-04-16 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
JP2020513815A (ja) * 2017-03-15 2020-05-21 ザ・ブロード・インスティテュート・インコーポレイテッド クラスター化短鎖反復回文配列エフェクター系に基づくウイルス検出用診断法
US20200199555A1 (en) * 2018-12-05 2020-06-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof
JP2020532968A (ja) * 2017-08-22 2020-11-19 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｒｎａ標的化方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP1025217B1 (en) 1997-10-24 2006-10-04 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
US10056224B2 (en) 2015-08-10 2018-08-21 Kla-Tencor Corporation Method and system for edge-of-wafer inspection and review
CA3028158A1 (en) * 2016-06-17 2017-12-21 The Broad Institute, Inc. Type vi crispr orthologs and systems
WO2019018423A1 (en) * 2017-07-17 2019-01-24 The Broad Institute, Inc. NEW TYPE VI CRISPR ORTHOLOGISTS AND ASSOCIATED SYSTEMS
CN107939288B (zh) 2017-11-14 2019-04-02 中国科学院地质与地球物理研究所 一种非旋转套的防转装置以及旋转导向装置
CN113348245A (zh) * 2018-07-31 2021-09-03 博德研究所 新型crispr酶和系统

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020511141A (ja) * 2017-03-15 2020-04-16 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
JP2020513815A (ja) * 2017-03-15 2020-05-21 ザ・ブロード・インスティテュート・インコーポレイテッド クラスター化短鎖反復回文配列エフェクター系に基づくウイルス検出用診断法
US20190002889A1 (en) * 2017-06-30 2019-01-03 Arbor Biotechnologies, Inc. Novel crispr rna targeting enzymes and systems and uses thereof
WO2019010422A1 (en) * 2017-07-07 2019-01-10 The Broad Institute, Inc. ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM
JP2020532968A (ja) * 2017-08-22 2020-11-19 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｒｎａ標的化方法および組成物
US20200199555A1 (en) * 2018-12-05 2020-06-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof
CN110656123A (zh) * 2019-10-12 2020-01-07 中国农业大学 基于CRISPR-Cas13d系统的sgRNA高效作用靶点的筛选方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABBOTT, T.R., ET AL.: ""Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza."", CELL, vol. 181, no. 4, JPN6025048501, 14 May 2020 (2020-05-14), pages 865 - 876, ISSN: 0005740615 *
LOTFI, M., ET AL.: ""CRISPR/Cas12: A potential therapeutic option of COVID-19."", BIOMEDICINE & PHARMACOTHERAPY, vol. 131, JPN6025048500, November 2020 (2020-11-01), pages 1 - 7, ISSN: 0005740616 *

Also Published As

Publication number Publication date
WO2022136370A1 (en) 2022-06-30
CN116917478A (zh) 2023-10-20
CA3203046A1 (en) 2022-06-30
EP4267736A1 (en) 2023-11-01
US20240041990A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US11446344B1 (en) Anellovirus compositions and methods of use
EP3080259B1 (en) Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
US20220119840A1 (en) Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
KR20240095525A (ko) 조작된 casx 억제 시스템
KR20210131310A (ko) 아넬로좀 및 사용 방법
KR20210125990A (ko) 단백질 대체 치료 양식을 운반하기 위한 아넬로좀
CN118973610A (zh) 通过中断细胞和病毒受体相互作用来阻断asfv感染的方法
Pals et al. Chemical strategies for antisense antibiotics
JP2024500932A (ja) Ｒｎａウイルスおよび／または細菌誘発性の疾患の治療に対するｃｒｉｓｐｒ／ｃａｓ１３の応用
CN101880677B (zh) 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用
JP2006523103A (ja) Ｒｎａ干渉組成物および方法
US11186838B2 (en) LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling
US20250382599A1 (en) Viral load-dependent crispr/cas13-system
JP2024532019A (ja) アルファ－１アンチトリプシン発現を阻害するための組成物及び方法
KR102839248B1 (ko) Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물
US20110142811A1 (en) Measles virus for the elimination of unwanted cell populations
JP2026502888A (ja) エピジェネティック調節因子の新規阻害剤
JP2026507918A (ja) 殺菌活性を有するペプチドグリカンヒドロラーゼ
KR101070654B1 (ko) 중증급성호흡기증후군 코로나바이러스(ｓｃｖ)에 대한 저해활성을 가지는 조성물
CN118556124A (zh) 经工程化的casx阻遏物系统
JP2004525602A (ja) 組織特異的および病原菌特異的毒性剤、リボザイム、ＤＮＡｚｙｍｅおよびアンチセンスオリゴヌクレオチドとそれらの使用方法
US20230140799A1 (en) DECOY TRANSCRIPTS FOR TREATMENT OF ssRNA VIRAL INFECTION
Scott et al. Pathogenic effects of Rift Valley fever virus NSs gene are alleviated in cultured cells by expressed antiviral short hairpin RNAs
CN117838832B (zh) Rbm25及其相关物质在抗病毒感染中的应用
US20260002151A1 (en) Compositions and methods for the modification and regulation of liver gene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260224